Tag: Aimovig

Data from multiple open-label extension studies, including one lasting five years, offer extensive information to help answer the crucial question: **Is Aimovig safe long term?**. These studies provide valuable insight into the sustained efficacy and long-term safety profile of the medication for migraine prevention.

Clinical trials for the migraine medication Aimovig (erenumab) did not report depression as a common side effect. However, given the well-documented link between migraine and mood disorders, the question, **does Aimovig cause depression**, is a critical concern for many patients navigating this treatment option.

Since its FDA approval in 2018, Aimovig (erenumab-aooe) has been a key player in migraine prevention [1.2.5]. Despite rumors, if you're asking 'Why was Aimovig discontinued?', the simple answer is: it hasn't been. The confusion stems from a significant change in its commercial partnership.

According to the Migraine Trust, calcitonin gene-related peptide (CGRP) monoclonal antibodies were the first medicines specifically designed to prevent migraine attacks. This newer class of drugs provides a definitive answer to the question, **what is the monthly injection for migraines?**, offering a proactive solution for people with frequent or chronic migraines.